NAMS (NewAmsterdam Pharma Company) Earnings per share for the last four quarters

NewAmsterdam Pharma N.V. (NAMS) - corporate logo

The promising image of NewAmsterdam Pharma (NAMS) in the therapy of cardiometabolic pathologies is confirmed by the annual EPS TTM delta on GURU.Markets, which captures a current trend where the indicator reached the level of 16.30. The integration of cholesterol-lowering agents into medical protocols strengthens the firm's role in the prevention of vascular risks. Successes in clinical trials help retain a staff of leading researchers and drug registration experts.

NAMS newamsterdampharma.com Net earnings per share (EPS TTM) (02/11/2024 - 11/18/2026)

NAMS (NewAmsterdam Pharma): analytical breakdowns and indicator data

- business market valuation indicators:
Fundamental company valuation:NAMS (NewAmsterdam Pharma Company)
Core merchandise of NewAmsterdam Pharma Corp

This indicator measures the percentage change in net income per share over the last twelve months relative to the same period last year, allowing short-term anomalies to be filtered out from sustainable growth. By analyzing the current EPS YoY TTM momentum, a conservative investor can confirm the effectiveness of capital raising for the scientific developments of NewAmsterdam Pharma (NAMS), assessing the extent to which clinical trial transparency converts into actual financial results.

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|MDGL (Madrigal Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|CORT: Earnings per share for the last four quarters|RYTM (Rhythm Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Akero Therapeutics|Net earnings per share (EPS TTM) MTSR|Earnings per share for the last twelve months MLTX (MoonLake Immunotherapeutics AG)|Earnings per share for the last twelve months crinetics.com CRNX|Soleno Therapeutics Corp (SLNO) - Net earnings per one share for the last twelve months|FOLD - Earnings per share for the last twelve months|ETNB: Earnings per share for the last twelve months|AGIO: Net earnings per share (EPS TTM)|GPCR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months MiMedx Corp|Rezolute Bio (RZLT) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months lexpharma.com (LXRX)|Net earnings per share for the last 12 months MBX Biosciences Inc MBX|Earnings per share for the last twelve months Altimmune ALT|Net earnings per share (EPS TTM) Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BioAge Labs, Inc BIOA|Biomea Fusion Inc (BMEA) - Earnings per share for the last twelve months|QNCX - Net earnings per share for the last four quarters|GUTS (Fractyl Health Inc.) - Net earnings per share (EPS TTM)|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS